Annual report pursuant to Section 13 and 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.24.1
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 17, 2019
Nov. 30, 2022
Jan. 31, 2018
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue recognized       $ 9,936,000 $ 14,880,000
Global Blood Therapeutics | Collaboration Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Initial period of research term 3 years        
Additional extension period for research term upon mutual agreement 1 year        
Additional extension period for research term   1 year      
Effective date of termination       Oct. 16, 2023  
Upfront payment receivable $ 20,000,000        
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses 40,000,000        
Milestone-based payment receivable $ 0        
Accounts receivable       $ 0  
Revenue recognized       9,900,000 13,600,000
Deferred revenue, short-term       0  
Global Blood Therapeutics | Collaboration Agreement | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Period of extension of initial research term 2 years        
Incyte          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue recognized       0 $ 1,300,000
Deferred revenue, short-term       0  
Incyte | Collaboration Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Total transaction price       12,800,000  
Upfront non-refundable and non-creditable payment       2,500,000  
Up-front consideration     $ 10,000,000    
Up-front consideration, cash     2,500,000    
Up-front consideration, pre-paid research funding     $ 7,500,000    
Prepaid research amount       7,500,000  
Premium paid on equity investment       2,300,000  
Collaboration agreement additional consideration incurred       $ 500,000